Compare Biogen Inc (BIIB) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dow Inc — how do they compare? Biogen Inc trades at $202.05 (market cap $30.13B), while Dow Inc trades at $30.94 (market cap $22.58B). The key difference: Biogen Inc is the larger of the two by market cap, and Dow Inc pays a 4.48% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DOW | |
|---|---|---|
Market Cap | $30.13B | $22.58B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $41.87 |
52-Week Low | $128.93 | $20.65 |
Enterprise Value | $37.20B | $38.27B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
DOW trades at $30.58, up 4.23% today, with a neutral technical signal and bullish moving averages. Recent earnings have consistently beaten estimates, but the company reported a net loss of -$2.62B in 2025, with declining revenue and negative profit margins. Cash flow from operations improved in 2025 to $1.03B, though debt levels have risen. The stock is trading below the analyst consensus price target of $35.11, with a mixed analyst rating of 33% buy, 53% hold, and 14% sell.
The outlook is cautious; while earnings beats and a dividend payment provide some support, persistent net losses, revenue declines, and rising debt pose significant risks. Investors should weigh the potential for operational turnaround against fundamental weaknesses and macroeconomic pressures on the chemicals sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
